Gene expression in cortex and hippocampus during acute pneumococcal meningitis [PDF]
, 2006 BACKGROUND: Pneumococcal meningitis is associated with high mortality (approximately 30%) and morbidity. Up to 50% of survivors are affected by neurological sequelae due to a wide spectrum of brain injury mainly affecting the cortex and hippocampus ...
Roney S Coimbra +6 more
core +2 more sources
Bruton's tyrosine kinase (Btk) inhibitor tirabrutinib suppresses osteoclastic bone resorption
Bone Reports, 2019 Osteoclasts are responsible for bone erosion in osteoporosis and rheumatoid arthritis (RA). Both Btk and Tec kinases have essential functions in osteoclast differentiation.
Yuko Ariza +3 more
doaj +1 more source
Bruton’s tyrosine kinase is a possible therapeutic target in microscopic polyangiitis
Arthritis Research & Therapy, 2023 Background Bruton’s tyrosine kinase (Btk) is an enzyme expressed in leukocytes other than T lymphocytes and plasma cells and involved in B-cell receptor- and Fcγ receptor (FcγR)-mediated signal transduction.
Issei Nakade +13 more
doaj +1 more source
Single cell imaging of Bruton's Tyrosine Kinase using an irreversible inhibitor [PDF]
, 2014 A number of Bruton's tyrosine kinase (BTK) inhibitors are currently in development, yet it has been difficult to visualize BTK expression and pharmacological inhibition in vivo in real time.
Kim, Eunha +4 more
core +1 more source
Editorial: Targeting Bruton Tyrosine Kinase
Frontiers in Cell and Developmental Biology, 2022 Brunner, C +4 more
openaire +5 more sources
Identification of pharmacodynamic biomarker hypotheses through literature analysis with IBM Watson.
PLoS ONE, 2019 BackgroundPharmacodynamic biomarkers are becoming increasingly valuable for assessing drug activity and target modulation in clinical trials. However, identifying quality biomarkers is challenging due to the increasing volume and heterogeneity of ...
Sonja Hatz +9 more
doaj +1 more source
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. [PDF]
, 2019 RESONATE-2 is a phase 3 study of first-line ibrutinib versus chlorambucil in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Patients aged ≥65 years (n = 269) were randomized 1:1 to once-daily ibrutinib 420 mg continuously or ...
Bairey, Osnat +19 more
core +3 more sources
The Role of BTK Inhibition in the Treatment of Chronic Lymphocytic Leukemia: A Clinical View
Journal of Experimental Pharmacology, 2021 Francesco Paolo Tambaro,1 Danilo De Novellis,1,2 William G Wierda3 1Unità Operativa di Trapianto di Midollo Osseo e Servizio Trasfusionale, Azienda Ospedaliera di Rilievo Nazionale Santobono-Pausilipon, Napoli, Italy; 2Department of Precision Medicine ...
Tambaro FP, De Novellis D, Wierda WG
doaj
Bruton’s Tyrosine Kinase: An Emerging Key Player in Innate Immunity
Frontiers in Immunology, 2017 Bruton’s tyrosine kinase (BTK) was initially discovered as a critical mediator of B cell receptor signaling in the development and functioning of adaptive immunity.
Alexander N. R. Weber +5 more
doaj +1 more source
Autoinhibition of Bruton's tyrosine kinase (Btk) and activation by soluble inositol hexakisphosphate
eLife, 2015 Bruton's tyrosine kinase (Btk), a Tec-family tyrosine kinase, is essential for B-cell function. We present crystallographic and biochemical analyses of Btk, which together reveal molecular details of its autoinhibition and activation.
Qi Wang +6 more
doaj +1 more source